injinji
Well-Known Member
It's been forty years since I was last in France, but it was too crowded then. I'm sure it has only gotten worse. Really is a shame they are making you guys go on living.
Will You Take The Vaccine?
- Thread starter Unclebaldrick
- Start date
zeddd
Well-Known Member
Kavanah uses hyperbole to speculate on unknown outcomes whilst admitting that patients with serious disease have prevented him from getting his cancer therapy. So yeah there is that
i've given birth 2x; how would you rate that against the bottom chart and 'not too horrible'?
discomfort is subjective. i have a friend flesh and blood (fresh out of quarantine) tell me 'it's death'..'do whatever you can to not get it'. she was vaxxed and boosted.
Last edited:
CunningCanuk
Well-Known Member
Wouldn’t the logistics of regulating vaccine distribution based on an individuals previous exposure be a daunting if not impossible task? How many asymptomatic people have had Covid and didn’t know? Is getting the vaccine after a previous infection a health risk?
zeddd
Well-Known Member
For the first part of your question I agree with you which is one reason why it should be patient choice rather than mandate. As to the second part yes there are lots of asymptomatic covid infections, nothing to worry about there, patient choice should be paramount if they are little risk to others or themselves, any subsequent infections should be mild due to memory cells waking up the immune response.
With regards to getting a vaccine after infection we don’t have the data for covid, but it is generally referred to as ADE, it happened with SARS 1 and the ferrets. Vaccine manufacturers are super aware of this possibility and we haven’t seen it so far, unless some of the rare adverse thromboses are to do with it, but Covid virus is more likely.
Last edited:
quite unique isn't he?
they dragged a chinese dude out of his house for quarantine camp and charged him about $800US for the trouble.
printer
Well-Known Member
Omicron largely evades immunity from past infection or two vaccine doses
The new report (Report 49) from the Imperial College London COVID-19 response team estimates that the risk of reinfection with the Omicron variant is 5.4 times greater than that of the Delta variant. This implies that the protection against reinfection by Omicron afforded by past infection may be as low as 19%.
Researchers estimate the growth and immune escape of the Omicron variant in England. They used data from the UKHSA and NHS for all PCR-confirmed SARS-CoV-2 cases in England who had taken a COVID test between November 29th and December 11th 2021.
The study includes people identified as having Omicron infection due to an S gene target failure (SGTF), as well as people with genotype data that confirmed Omicron infection. Overall, 196,463 people without S gene target failure (likely to be infected with another variant) and 11,329 cases with it (likely to be infected with Omicron) were included in the SGTF analysis, as well as 122,063 Delta and 1,846 Omicron cases in the genotype analysis.
To assess the impact of Omicron on reinfection rates the researchers used genotype data, since even prior to Omicron, reinfection was correlated with negative S gene Target Failure data, likely due to random PCR target failure caused by the lower viral loads associated with reinfections.
Controlling for vaccine status, age, sex, ethnicity, asymptomatic status, region and specimen date, Omicron was associated with a 5.40 (95% CI: 4.38-6.63) fold higher risk of reinfection compared with Delta. To put this into context, in the pre-Omicron era, the UK “SIREN” study of COVID infection in healthcare workers estimated that prior infection afforded 85% protection against a second COVID infection over 6 months. The reinfection risk estimated in the current study suggests this protection has fallen to 19% (95%CI: 0-27%) against an Omicron infection.
The researchers found a significantly increased risk of developing a symptomatic Omicron case compared to Delta for those who were two or more weeks past their second vaccine dose, and two or more weeks past their booster dose (for AstraZeneca and Pfizer vaccines).
Depending on the estimates used for vaccine effectiveness against symptomatic infection from the Delta variant, this translates into vaccine effectiveness estimates against symptomatic Omicron infection of between 0% and 20% after two doses, and between 55% and 80% after a booster dose. Similar estimates were obtained using genotype data, albeit with greater uncertainty.
Prof Neil Ferguson from Imperial College London said: “This study provides further evidence of the very substantial extent to which Omicron can evade prior immunity given by both infection or vaccination. This level of immune evasion means that Omicron poses a major, imminent threat to public health.”
www.imperial.ac.uk
The new report (Report 49) from the Imperial College London COVID-19 response team estimates that the risk of reinfection with the Omicron variant is 5.4 times greater than that of the Delta variant. This implies that the protection against reinfection by Omicron afforded by past infection may be as low as 19%.
Researchers estimate the growth and immune escape of the Omicron variant in England. They used data from the UKHSA and NHS for all PCR-confirmed SARS-CoV-2 cases in England who had taken a COVID test between November 29th and December 11th 2021.
The study includes people identified as having Omicron infection due to an S gene target failure (SGTF), as well as people with genotype data that confirmed Omicron infection. Overall, 196,463 people without S gene target failure (likely to be infected with another variant) and 11,329 cases with it (likely to be infected with Omicron) were included in the SGTF analysis, as well as 122,063 Delta and 1,846 Omicron cases in the genotype analysis.
To assess the impact of Omicron on reinfection rates the researchers used genotype data, since even prior to Omicron, reinfection was correlated with negative S gene Target Failure data, likely due to random PCR target failure caused by the lower viral loads associated with reinfections.
Controlling for vaccine status, age, sex, ethnicity, asymptomatic status, region and specimen date, Omicron was associated with a 5.40 (95% CI: 4.38-6.63) fold higher risk of reinfection compared with Delta. To put this into context, in the pre-Omicron era, the UK “SIREN” study of COVID infection in healthcare workers estimated that prior infection afforded 85% protection against a second COVID infection over 6 months. The reinfection risk estimated in the current study suggests this protection has fallen to 19% (95%CI: 0-27%) against an Omicron infection.
The researchers found a significantly increased risk of developing a symptomatic Omicron case compared to Delta for those who were two or more weeks past their second vaccine dose, and two or more weeks past their booster dose (for AstraZeneca and Pfizer vaccines).
Depending on the estimates used for vaccine effectiveness against symptomatic infection from the Delta variant, this translates into vaccine effectiveness estimates against symptomatic Omicron infection of between 0% and 20% after two doses, and between 55% and 80% after a booster dose. Similar estimates were obtained using genotype data, albeit with greater uncertainty.
Prof Neil Ferguson from Imperial College London said: “This study provides further evidence of the very substantial extent to which Omicron can evade prior immunity given by both infection or vaccination. This level of immune evasion means that Omicron poses a major, imminent threat to public health.”
Omicron largely evades immunity from past infection or two vaccine doses | Imperial News | Imperial College London
The Omicron variant largely evades immunity from past infection or two vaccine doses according to the latest Imperial modelling.
www.imperial.ac.uk
CatHedral
Well-Known Member
After reading about asymptomatic cases degenerating into full long Covid, I do not say “nothing to worry about there”. I worry.
slipdef
Well-Known Member
Please erase/close my account please, i have nothing to do in RIU, my mistake.You may be correct that they are idiots. Or maybe they are just susceptible to conspiracy theories.
Either way, it's certain that they just don't understand.
CunningCanuk
Well-Known Member
I worry about that too. Since there’s so much we don’t know, my instinct is to err on the side of caution.
CatHedral
Well-Known Member
Come to think of it, it has been that long. The South is simply beautiful. I fondly remember the cars and light delivery vehicles. (And being a skinny teen sipping a beer at an outdoor table.) The cars were so dog butt ugly they became kind of cute.
Now it’s all bland international shapes. A cultural treasure (?), gone.
CunningCanuk
Well-Known Member
CatHedral
Well-Known Member
Fify
zeddd
Well-Known Member
One swallow does not a summer make, I agree. It’s always important to understand incidence within a population, long covid from asymptomatic infection could easily also be a case of cfs or ebv as these post dromal syndromes appear similar to long covid. The other point is long covid from asymptomatic infection is rare, there will be cases and these are the ones you read about. Meanwhile in the U.K. today 200 people died of type 2 diabetes and prob >400 of cancer, but don’t worry if you’ve missed it cos it’s the same story every day.